[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics insider Neil G. Almstead completed matched option exercises and open-market sales totaling 55,000 shares on 10/03/2025. The transactions were executed under a Rule 10b5-1 plan adopted on 12/10/2024, and consisted of two option exercises at an exercise price of $30.86 (total 55,000 shares acquired) and multiple sales at weighted-average prices ranging from $65.45 to $67.16. After these actions the reporting person directly holds 100,625 shares and the reporting persons spouse holds 6,179 shares indirectly; the report also notes 272 shares purchased through the employee stock purchase plan for the period ended 6/30/2025.

The filing shows the exercises funded sales executed the same day (net zero change from the matched option exercises and sales), and the reporting person certified the trades via an attorney-in-fact signature on 10/07/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan adopted on 12/10/2024, indicating pre-planned execution
• Option exercises at $30.86 followed by sales, converting compensation into liquidity
• Reporting person retains substantial stake with 100,625 shares directly and 6,179 indirectly

Negative

• Significant same-day sales of 55,000 shares (total sold), which reduced immediately available exercised shares
• Multiple sale tranches at higher weighted-average prices indicate active disposals on 10/03/2025

Insights

Corporate Governance Analyst

Matched exercises and sales under a 10b5-1 plan show pre-planned liquidity, not ad-hoc disposition.

The report discloses that the transactions were effected pursuant to a written Rule 10b5-1 plan adopted on 12/10/2024, which provides an affirmative defense against insider trading claims when properly documented and executed. The reporting person exercised stock options at an exercise price of $30.86 and contemporaneously sold the resulting shares in multiple trades at weighted-average prices between $65.45 and $67.16, realizing immediate gross proceeds from the sales.

Key items to watch in the near term include any subsequent Form 4 filings that would show changes in holdings or additional 10b5-1 activity, and whether future exercises produce similar matched sales; these near-term items are monitorable through periodic SEC filings.

Equity Compensation Analyst

The filing shows option exercises converted to shares and sold the same day, leaving direct holdings at 100,625 shares.

The report lists two stock option exercises that together produced 55,000 shares exercisable and sold the same day, executed at an exercise price of $30.86. The individual retains 100,625 shares directly after the transactions, plus 6,179 indirectly via spouse; additionally, 272 shares came from the ESPP period ended 6/30/2025.

For compensation and dilution context, monitor future option grants, vesting schedules, and any disclosures of equity plan share pools in upcoming filings to assess potential dilution over the next 12 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		M(1)		3,442	A	$30.86	104,067(2)	D
Common Stock	10/03/2025		S(1)		1,609	D	$65.46(3)	102,458	D
Common Stock	10/03/2025		S(1)		1,760	D	$66.56(4)	100,698	D
Common Stock	10/03/2025		S(1)		73	D	$67.16	100,625	D
Common Stock	10/03/2025		M(1)		51,558	A	$30.86	152,183	D
Common Stock	10/03/2025		S(1)		23,419	D	$65.45(5)	128,764	D
Common Stock	10/03/2025		S(1)		23,863	D	$66.45(6)	104,901	D
Common Stock	10/03/2025		S(1)		4,276	D	$67.15(7)	100,625	D
Common Stock								6,179(2)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.86	10/03/2025		M(1)			3,442	(8)	01/03/2026	Common Stock	3,442	$0	51,558	D
Stock Option (Right to Buy)	$30.86	10/03/2025		M(1)			51,558	(8)	01/03/2026	Common Stock	51,558	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024

2. Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.15 to $67.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

8. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PTC Therapeutics insider Neil G. Almstead trade on 10/03/2025 (PTCT)?

The insider exercised options totaling 55,000 shares at an exercise price of $30.86 and sold 55,000 shares in multiple trades on 10/03/2025.

Were these trades part of a pre-planned program for PTCT insiders?

Yes. The transactions were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on 12/10/2024.

What were the sale prices reported in the Form 4 for PTCT insider trades?

Weighted-average sale prices reported range from $65.45 to $67.16 per share across multiple trades.

How many PTCT shares does the reporting person hold after the transactions?

The reporting person directly holds 100,625 shares after the reported transactions; the spouse holds 6,179 shares indirectly; additionally, 272 shares were acquired under the ESPP for the period ended 6/30/2025.

Did the Form 4 report any option activity besides exercises?

Yes. The Form 4 shows two stock option exercises that produced 55,000 underlying shares exercisable and sold the same day; the options were exercisable immediately.